z-logo
open-access-imgOpen Access
Measuring Histone Deacetylase Inhibition in the Brain
Author(s) -
Reddy Doodipala Samba,
Wu Xin,
Golub Victoria M.,
Dashwood W. Mohaiza,
Dashwood Roderick H.
Publication year - 2018
Publication title -
current protocols in pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.893
H-Index - 26
eISSN - 1934-8290
pISSN - 1934-8282
DOI - 10.1002/cpph.41
Subject(s) - histone deacetylase , epigenetics , acetylation , histone , neuroprotection , chemistry , hdac1 , biochemistry , resveratrol , histone deacetylase 5 , biology , pharmacology , dna , gene
Histone deacetylases (HDACs) represent a family of enzymes that are targets for epigenetic modulation of genomic activity and may be beneficial in the treatment of many diseases, including cancer and central nervous system disorders. In animal models, HDAC inhibitors have neuroprotective, antiepileptogenic, and antidepressant effects. Assaying HDAC activity provides a robust method for identifying HDAC inhibitors and for assessing their effects under various physiological conditions or after pathological insults. In this unit, a simple and sensitive assay for measuring HDAC activity is described. HDAC activity in tissue lysates can be assessed fluorometrically using a Boc‐Lys(Ac) HDAC activity kit. HDACs catalyze the deacetylation of the substrate Boc‐Lys(Ac)‐AMC. Addition of a trypsin‐containing developer converts the deacetylated product to a quantifiable fluorophore that can be used both as a screening method to identify putative HDAC inhibitors and to assess the effects of these inhibitors on tissue and animal epigenetic‐modulated phenotypes. © 2018 by John Wiley & Sons, Inc.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom